ZOLL Announces Successful Bid to Acquire Vyaire Medical

Completion of acquisition is subject to court approval and dependent on a successful closing

ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it is the winning bidder in an auction to acquire Vyaire Medical’s ventilator business as part of Vyaire’s Chapter 11 bankruptcy proceedings. Completion of the acquisition is subject to court approval at a sale hearing and dependent on a successful closing that is anticipated to occur in the coming weeks.

ZOLL is a global leader in acute critical care and related software and diagnostic tools, and its solutions are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory conditions. Since 2014, ZOLL has manufactured ventilation devices and accessories designed for the transport of critically ill patients.

“Respiratory care has been central to ZOLL’s business strategy for many years,” said Jon Rennert, CEO of ZOLL. “If the acquisition is successfully completed, adding Vyaire’s ventilators to ZOLL’s product portfolio will enhance our ability to serve a broader range of clinicians and patients.”

Until new ownership is final, Vyaire ventilator customers should continue to contact Vyaire (for details visit https://www.vyaire.com/contact-us).

Additional Background

On June 10, 2024, Vyaire Medical announced it had voluntarily filed for Chapter 11 bankruptcy protection in the U.S. The Chapter 11 filing allowed Vyaire to continue to operate while seeking to sell its business units, including the Vyaire ventilation business. Since filing for bankruptcy, day-to-day operations at Vyaire have continued with little interruption, and Vyaire has continued to serve its ventilator customers and maintain the team needed to operate safely and efficiently.

SourceZOLL®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”